GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Cyclically Adjusted PS Ratio

XOMA (XOMA Royalty) Cyclically Adjusted PS Ratio : 7.69 (As of May. 30, 2025)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Cyclically Adjusted PS Ratio?

As of today (2025-05-30), XOMA Royalty's current share price is $24.90. XOMA Royalty's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $3.24. XOMA Royalty's Cyclically Adjusted PS Ratio for today is 7.69.

The historical rank and industry rank for XOMA Royalty's Cyclically Adjusted PS Ratio or its related term are showing as below:

XOMA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.06   Med: 1.77   Max: 10.11
Current: 7.87

During the past years, XOMA Royalty's highest Cyclically Adjusted PS Ratio was 10.11. The lowest was 0.06. And the median was 1.77.

XOMA's Cyclically Adjusted PS Ratio is ranked worse than
62.1% of 496 companies
in the Biotechnology industry
Industry Median: 5.365 vs XOMA: 7.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

XOMA Royalty's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.243. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Royalty Cyclically Adjusted PS Ratio Historical Data

The historical data trend for XOMA Royalty's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Cyclically Adjusted PS Ratio Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.83 3.85 4.21 5.29 8.12

XOMA Royalty Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.88 6.94 8.00 8.12 6.15

Competitive Comparison of XOMA Royalty's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, XOMA Royalty's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Cyclically Adjusted PS Ratio falls into.


;
;

XOMA Royalty Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

XOMA Royalty's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=24.90/3.24
=7.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, XOMA Royalty's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.243/134.9266*134.9266
=0.243

Current CPI (Mar. 2025) = 134.9266.

XOMA Royalty Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.432 100.684 0.579
201509 0.350 100.392 0.470
201512 8.106 99.792 10.960
201603 0.663 100.470 0.890
201606 0.074 101.688 0.098
201609 0.105 101.861 0.139
201612 0.087 101.863 0.115
201703 0.038 102.862 0.050
201706 1.425 103.349 1.860
201709 4.373 104.136 5.666
201712 0.591 104.011 0.767
201803 0.056 105.290 0.072
201806 0.270 106.317 0.343
201809 0.107 106.507 0.136
201812 0.200 105.998 0.255
201903 0.872 107.251 1.097
201906 0.110 108.070 0.137
201909 0.938 108.329 1.168
201912 0.047 108.420 0.058
202003 0.082 108.902 0.102
202006 0.041 108.767 0.051
202009 0.051 109.815 0.063
202012 1.915 109.897 2.351
202103 0.033 111.754 0.040
202106 0.080 114.631 0.094
202109 0.083 115.734 0.097
202112 2.407 117.630 2.761
202203 0.274 121.301 0.305
202206 0.086 125.017 0.093
202209 0.039 125.227 0.042
202212 0.130 125.222 0.140
202303 0.038 127.348 0.040
202306 0.145 128.729 0.152
202309 0.072 129.860 0.075
202312 0.160 129.419 0.167
202403 0.129 131.776 0.132
202406 0.326 132.554 0.332
202409 0.063 133.029 0.064
202412 0.197 133.157 0.200
202503 0.243 134.927 0.243

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA Royalty  (NAS:XOMA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


XOMA Royalty Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Executives
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Joseph M Limber director ACLARA BIOSCIENCES INC, 1288 PEAR AVE, MOUNTAIN VIEW CA 94043
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555